ASTELLAS PHARMA EUROPE BV

Their core work

Astellas Pharma Europe is the European headquarters of the Japanese pharmaceutical company Astellas, based in Leiden, Netherlands. They contribute industry expertise to large-scale public-private research partnerships focused on drug development, clinical evidence generation, and advanced therapies. Their H2020 involvement centers on improving how drugs are discovered, tested, and delivered to patients — spanning biomarker-driven personalized medicine, real-world evidence, AI-powered drug discovery, and gene/cell therapies for rare diseases. As a major pharma company, they bring clinical trial infrastructure, regulatory knowledge, and proprietary compound libraries to consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2018), Astellas focused on disease-specific biomarker research, personalized medicine for chronic conditions like diabetic kidney disease, and building real-world evidence frameworks for regulatory decision-making. From 2019 onward, their focus shifted markedly toward digital and computational approaches — federated learning for drug discovery, advanced gene/cell therapies, and pandemic-driven drug repurposing. This evolution mirrors the broader pharma industry's pivot from traditional clinical research toward AI-enabled R&D and next-generation therapeutics.

Astellas is moving toward computationally driven drug development and advanced therapeutic modalities (gene/cell therapy), signaling interest in partners with AI, bioinformatics, or ATMP manufacturing expertise.

How they like to work

Astellas participates exclusively as a consortium partner, never as coordinator — consistent with how large pharma companies typically engage in IMI and Horizon 2020 projects, contributing industry data and expertise while academic partners lead. With 203 unique partners across 23 countries, they operate within large multi-stakeholder consortia (typical of IMI public-private partnerships). This means working with Astellas involves joining well-funded, multi-year initiatives where the company provides clinical compounds, patient data access, or regulatory experience rather than driving project management.

Astellas has built a broad European network of 203 unique partners across 23 countries, reflecting the large IMI-style consortia they participate in. Their partnerships span academic medical centers, other pharmaceutical companies, regulatory bodies, and patient organizations across nearly all EU member states.

What sets them apart

Astellas brings the resources of a top-20 global pharmaceutical company to EU research consortia — proprietary compound libraries, clinical trial infrastructure, and deep regulatory expertise that academic partners cannot replicate. Their participation in MELLODDY (where 10 pharma companies pooled predictive models without sharing data) demonstrates willingness to engage in pre-competitive collaboration on sensitive assets. For consortium builders, Astellas offers credibility with regulators, access to industry-scale datasets, and a track record of sustained multi-year commitment to public-private partnerships.

Highlights from their portfolio

• MELLODDY
  Landmark project where 10 major pharma companies used federated learning to collaboratively train drug discovery models without exposing proprietary chemical data — a first-of-its-kind approach.
• T2EVOLVE
  Addresses one of the most high-profile areas in modern oncology — CAR-T and TCR-engineered cell therapies — combining GMP manufacturing, preclinical models, and patient access challenges.
• BEAt-DKD
  Large-scale 7-year initiative to develop biomarker-driven personalized treatment for diabetic kidney disease, integrating clinical trials with multi-omics data.